China CAS:2921-57-5 Manufacturer

We thinks what shoppers think, the urgency of urgency to act during the interests of a buyer position of basic principle, allowing for greater top quality, lessen processing costs, costs are extra reasonable, won the new and previous buyers the support and affirmation for CAS:2921-57-5, Excellent excellent, competitive selling prices, prompt delivery and dependable provider are guaranteed Kindly let us know your quantity requirement under each size category so that we will inform you accordingly.
CAS:2921-57-5, Ought to any of these products be of curiosity to you, make sure you let us know. We will be satisfied to provide you a quotation on receipt of one's in depth specifications. We have now our personalized experienced R&D enginners to meet any of one's requriements, We appear forward to receiving your enquires soon'and hope to have the opportunity to work together with you in the future. Welcome to check out our company.

Hot Products

  • Levonorgestrel

    Levonorgestrel

    Levonorgestrel has speficications of CP/EP/USP. DMF,GMP and CEP available.

    CAS:797-63-7

  • Tibolone

    Tibolone

    Tibolone complies with EP specification. DMF is approved.

    CAS:5630-53-5

  • Nintedanib Esylate

    Nintedanib Esylate

    Nintedanib Esylate has in-house specification. DMF available.

    CAS:656247-18-6

  • 21-acetoxy-11β-hydroxypregna-1,4,16-triene-3,20-dione

    21-acetoxy-11β-hydroxypregna-1,4,16-triene-3,20-dione

    21-Acetoxy-11β-hydroxypregna-1,4,16-triene-3,20-dione is an intermediate in the synthesis of Budesonide (B689490) related derivatives.

    CAS:3044-42-6

  • Mifepristone Tablets

    Mifepristone Tablets

    Mifepristone Tablets Specifications:10mg*1
    Indications:Emergency Contraceptive
  • Abiraterone

    Abiraterone

    Abiraterone is a steroidal cytochrome P 450 17α-hydroxylase-17,20-lyase inhibitor (CYP17), It is used in combination with prednisone to treat patients with metastatic castration-resistant prostate cancer (prostate cancer that is resistant to medical or surgical treatments that lower testosterone and has already spread to other parts of the body) and metastatic high-risk castration-sensitive prostate cancer.

    CAS:154229-19-3

Send Inquiry

X
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies. Privacy Policy
Reject Accept